DRUG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

-1.395

-14050%

-1.965

+367.86%

-2.735

+269.59%

Estimates Revision

The market is revising No Change the revenue expectations for Bright Minds Biosciences Inc. (DRUG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 46.57%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+46.57%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast DRUG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRUG is 79.10 USD with a low forecast of 71.49 USD and a high forecast of 84.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

71.49

Averages

79.10

High

84.40

Current: 0.000

Low

71.49

Averages

79.10

High

84.40

Baird

NULL -> Outperform

upgrade

$82 -> $142

2026-01-07

New

Reason

Baird

Price Target

$82 -> $142

2026-01-07

New

upgrade

NULL -> Outperform

Reason

Baird raised the firm's price target on Bright Minds to $142 from $82 and keeps an Outperform rating on the shares. The firm updated its model following the release of data from its BMB-101 trial data which showed an absence of seizures.

BTIG

NULL -> Buy

upgrade

$72 -> $147

2026-01-07

New

Reason

BTIG

Price Target

$72 -> $147

2026-01-07

New

upgrade

NULL -> Buy

Reason

BTIG raised the firm's price target on Bright Minds to $147 from $72 and keeps a Buy rating on the shares. The first readout for BMB-101 in absence seizures was very strong, showing a 73% reduction in a heavily pre-treated cohort, highlighting its potential as a salvage therapy in a large market with few well-tolerated options, the analyst tells investors in a research note. While efficacy appears impressive across lines, further evaluation of safety and data in earlier treatment lines will be key, as the company plans pivotal trials for both absence seizures and Developmental and Epileptic Encephalopathies, with promising implications for Prader-Willi Syndrome given the drug's targeted mechanism, the firm says.

Baird

NULL -> Outperform

maintain

$75 -> $82

2025-11-07

Reason

Baird

Price Target

$75 -> $82

2025-11-07

maintain

NULL -> Outperform

Reason

Baird raised the firm's price target on Bright Minds to $82 from $75 and keeps an Outperform rating on the shares. The firm updated its model as the BMB-105 Pader-Willi program holds promise.

BTIG

initiated

$72

2025-09-08

Reason

BTIG

Price Target

$72

2025-09-08

initiated

Reason

BTIG initiated coverage of Bright Minds with a Buy rating and $72 price target. The company is developing a \"very specific\" 5-HT2C agonist, BMB-101, for epilepsies that has better dosing than bexicaserin, the analyst tells investors in a research note. The firm believes the dosing advantage is relevant given data suggesting the side effects of the 5-HT2C class may be peak concentration-dependent. The relatively high percentage of absence seizures in otherwise healthy children suggests convenient dosing and low side effects \"are a major positive,\" contends BTIG. It expects Phase 2 data from Bright Minds around year-end 2025.

Cantor Fitzgerald

Overweight

initiated

2025-07-02

Reason

Cantor Fitzgerald

Price Target

2025-07-02

initiated

Overweight

Reason

Cantor Fitzgerald assumed coverage of Bright Minds with an Overweight rating and no price target. Bright Minds' lead asset, BMB-101, is a highly selective 5-HT2C receptor agonist in developmental and epileptic encephalopathies and absence epilepsy, the analyst tells investors in a research note. BMB-101 may deliver improved efficacy, safety, and durability vs. competitors, the firm says.

TD Cowen

Joseph Thome

Buy

initiated

2025-05-13

Reason

TD Cowen

Joseph Thome

Price Target

2025-05-13

initiated

Buy

Reason

TD Cowen analyst Joseph Thome initiated coverage of Bright Minds with a Buy rating and no price target. The company's lead asset BMB-101 is a biased 5-HT2C agonist that has the potential to be best in class for the treatment of certain refractory seizure disorders, the analyst tells investors in a research note. The firm says its key opinion leaders have highlighted the unmet need by current options in absence epilepsy.

Valuation Metrics

The current forward P/E ratio for Bright Minds Biosciences Inc (DRUG.O) is -17.40, compared to its 5-year average forward P/E of -3.78. For a more detailed relative valuation and DCF analysis to assess Bright Minds Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.78

Current PE

-17.40

Overvalued PE

3.87

Undervalued PE

-11.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.45

Current EV/EBITDA

-7.92

Overvalued EV/EBITDA

1.41

Undervalued EV/EBITDA

-4.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

DRUG News & Events

Events Timeline

No data

News

8.5

01-08Globenewswire

PinnedBright Minds Biosciences Prices 1.945M Shares at $90 for $175.05M Offering

9.5

01-07Benzinga

Innovative Eyewear Inc Reports 45% Year-over-Year Sales Growth in Q4

8.5

01-07Benzinga

Bright Minds Biosciences Launches $100 Million Public Offering

People Also Watch

Frequently Asked Questions

What is Bright Minds Biosciences Inc (DRUG) stock price today?

The current price of DRUG is 90.01 USD — it has decreased -6.22 % in the last trading day.

What is Bright Minds Biosciences Inc (DRUG)'s business?

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

What is the price predicton of DRUG Stock?

What is Bright Minds Biosciences Inc (DRUG)'s revenue for the last quarter?

Bright Minds Biosciences Inc revenue for the last quarter amounts to -5.66M USD, increased 617.28 % YoY.

What is Bright Minds Biosciences Inc (DRUG)'s earnings per share (EPS) for the last quarter?

Bright Minds Biosciences Inc. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Bright Minds Biosciences Inc (DRUG)'s fundamentals?

How many employees does Bright Minds Biosciences Inc (DRUG). have?

Bright Minds Biosciences Inc (DRUG) has 0 emplpoyees as of January 09 2026.

What is Bright Minds Biosciences Inc (DRUG) market cap?

Today DRUG has the market capitalization of 700.92M USD.